Prognostic significance of plasma osteopontin in patients with locoregionally advanced head and neck squamous cell carcinoma treated on TROG 02.02 phase III trial.
about
Trial WatchTargeting the hypoxic fraction of tumours using hypoxia-activated prodrugsThe clinical importance of assessing tumor hypoxia: relationship of tumor hypoxia to prognosis and therapeutic opportunitiesCurrent relevance of hypoxia in head and neck cancerInfluence of hypoxia and irradiation on osteopontin expression in head and neck cancer and glioblastoma cell lines.Interleukin 4, interleukin 6 and osteopontin-serological markers of head and neck malignancy in primary diagnostics: A pilot studyPrognostic and predictive values of SPP1, PAI and caveolin-1 in patients with oral squamous cell carcinoma.Prognostic and predictive significance of plasma HGF and IL-8 in a phase III trial of chemoradiation with or without tirapazamine in locoregionally advanced head and neck cancer.Osteopontin Fragments with Intact Thrombin-Sensitive Site Circulate in Cervical Cancer PatientsPerioperative changes in osteopontin and TGFβ1 plasma levels and their prognostic impact for radiotherapy in head and neck cancer.Individualization of cancer treatment from radiotherapy perspective.Role of osteopontin in the pathophysiology of cancer.Efficient Protocol for the Identification of Hypoxic Cell Radiosensitisers.Serum, plasma and saliva biomarkers for head and neck cancer.Targeting Hypoxia to Improve Non-Small Cell Lung Cancer Outcome.Monitoring early response to chemoradiotherapy with 18F-FMISO dynamic PET in head and neck cancer.Correlation of hypoxia status with radiosensitizing effects of sodium glycididazole: A preclinical study.
P2860
Q24618653-177276A1-A6E6-4483-AED0-A444C4BBE8B6Q26774750-154976A6-F307-4241-A124-81BAB13502D9Q27025579-FE3F6141-7797-4C28-AB8A-FFD2E315DC95Q28074577-278311D2-E8BA-49B6-ABEF-3D695CFC4866Q30316284-15A5A367-D846-4853-8362-69E5DAB3B810Q33967476-DCBB6384-6ED7-438F-9510-BD83B231D32DQ34371552-26B57432-5BAE-4EA9-B47A-9591A0E2E7DEQ35836427-9F3ED23E-EF77-4DEC-B623-359EBFE37B9AQ36095801-F20046AF-FAD6-467A-860A-ECF05E7A2FEDQ36238876-0BB1911F-E051-416F-B1FE-BE31DCF28BCFQ37989616-DE795EBD-623A-4556-A2A8-D8915EB07584Q38198463-AC308384-A03B-4895-B053-E40E0505E90AQ39668588-46D7782A-F372-486C-84E3-206E18A5DF09Q47405806-C46B9F5F-4E1B-4DB6-9694-E0344CC0B72CQ47769995-B3E58A07-CF60-4CDB-8BE6-13C0D2B40E67Q48105710-B8D95EFA-36DB-4355-8479-13DCD997A5C1Q55230222-B7DAC0EB-746B-46A1-8967-B56C2565A2F3
P2860
Prognostic significance of plasma osteopontin in patients with locoregionally advanced head and neck squamous cell carcinoma treated on TROG 02.02 phase III trial.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Prognostic significance of pla ...... on TROG 02.02 phase III trial.
@ast
Prognostic significance of pla ...... on TROG 02.02 phase III trial.
@en
type
label
Prognostic significance of pla ...... on TROG 02.02 phase III trial.
@ast
Prognostic significance of pla ...... on TROG 02.02 phase III trial.
@en
prefLabel
Prognostic significance of pla ...... on TROG 02.02 phase III trial.
@ast
Prognostic significance of pla ...... on TROG 02.02 phase III trial.
@en
P2093
P2860
P1476
Prognostic significance of pla ...... on TROG 02.02 phase III trial.
@en
P2093
Amato Giaccia
Annette M Lim
Daniel Truong
Danny Rischin
Hongbin Cao
Kathleen Kwok
Lester Peters
Quynh-Thu Le
Richard Fisher
Richard J Young
P2860
P304
P356
10.1158/1078-0432.CCR-11-2295
P407
P577
2011-11-17T00:00:00Z